CLSD - Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Clearside Biomedical, Inc. (Nasdaq: CLSD), a pioneering biopharmaceutical company focused on innovative treatment delivery to the back of the eye, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. This event will feature George Lasezkay, PharmD, JD, President and CEO, alongside Victor Chong, M.D., MBA, Chief Medical Officer and EVP of Research & Development, engaging in a fireside chat scheduled for April 7, 2025, at 12:45 p.m. ET. Investors and interested parties can access the live stream and post-event archive via the Clearside website.

Clearside Biomedical is at the forefront of transforming ocular healthcare with its proprietary suprachoroidal space (SCS) injection platform. This innovative technology allows for a minimally invasive, in-office procedure that enables targeted delivery of various therapies directly to the macula, retina, and choroid, enhancing patient outcomes in managing sight-threatening diseases. The SCS Microinjector® facilitates this repeatable method, allowing practitioners to administer medications effectively without surgical intervention.

The company's leading product in development is CLS-AX, an injectable suspension of axitinib aimed at treating neovascular age-related macular degeneration (wet AMD), with plans for a Phase 3 trial underway. Additionally, Clearside is exploring new small molecule candidates for the long-term treatment of geographic atrophy (GA). The firm has successfully launched its first product, XIPERE® (triamcinolone acetonide injectable suspension), which has been approved for suprachoroidal use and is currently marketed through a commercial partner.

Beyond its developments, Clearside is also strategically collaborating with other companies to expand its reach within the ophthalmic therapeutics landscape. For more information, stakeholders are encouraged to visit clearsidebio.com or follow the company on social media platforms.

As Clearside Biomedical, Inc. (Nasdaq: CLSD) prepares to participate in the 24th Annual Needham Virtual Healthcare Conference, it offers a timely opportunity for investors to delve into the company’s innovative position within the biopharmaceutical sector. During the fireside chat, the insights shared by CEO George Lasezkay and CMO Victor Chong could provide valuable information regarding Clearside's strategic advancements, particularly regarding its proprietary suprachoroidal space (SCS®) injection platform.

The focus of Clearside’s ongoing research, including its lead program CLS-AX for neovascular age-related macular degeneration (wet AMD), is important for both patient outcomes and market potential. Given the aging global population, demand for effective treatments targeting sight-threatening eye diseases is on the rise, and Clearside’s platform seeks to fulfill this need with less invasive procedures. Investors should closely observe the company’s progress toward its anticipated Phase 3 program, as successful results could significantly enhance Clearside's market position and valuation.

Additionally, it’s worth noting Clearside's commercialization of XIPERE® and ongoing partnerships, which underscore a strategic approach to leverage the SCS Microinjector in collaboration with other innovators—broadening its therapeutic offerings and potentially stabilizing revenue streams.

For investors and stakeholders, keeping an eye on developments shared at the conference could yield insights into prospective collaborations, pipeline advancements, and updates on market strategy. As Clearside continues to navigate clinical trials and regulatory pathways, it represents a compelling investment opportunity within the ophthalmic therapeutic landscape, particularly for those focused on cutting-edge biopharmaceutical innovations. Overall, maintaining a watchful eye on this evolving narrative could provide strategic advantages for discerning investors.